Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 12, 2009

View Archived Issues

Novel flavivirus-based vaccine protects against Dengue virus type 2 in mice

Pharmacokinetics, toxicity of IQP-0410 investigated in dogs

Alfadolone confers antinociception in rat models of inflammation

Avexa provides update on merger with Progen

Bavituximab achieves primary endpoint in phase II breast cancer study

Living Cell Technologies reports interim Diabecell Implants results

Prezista available for pediatric patients as part of HIV combination therapy

Genta submits tesetaxel trial proposal for SPA in advanced gastric cancer

Endo signs research collaboration agreements with Harvard University and Aurigene

Oxygen to file in Switzerland for phase II clinical trial of Oxycyte in TBI

TorreyPines reports positive results from phase I clinical trial of NGX-426 in healthy subjects

VasoGenix selects lead CGRP agonist analogue to develop for heart failure

Chewable antiretroviral therapy combination viable in HIV-infected children

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...